Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
03/28/20 3:41 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Mar 12 2020
Summary ToggleAdverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results
- Mar 11 2020
Summary ToggleAdverum Biotechnologies Announces Data Presentations at ARVO 2020
- Mar 5 2020
Summary ToggleAdverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
- Feb 25 2020
Summary ToggleAdverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer
There are currently no events to display.